Natera

Natera develops cell-free DNA (cfDNA) tests and genetic diagnostics aimed at detecting disease at its earliest stages. Its work spans oncology, women's health and organ health, combining molecular biology, bioinformatics software, artificial intelligence and single-molecule detection techniques. The company reports detection sensitivity down to a single molecule in a tube of blood.

Three tests anchor the product portfolio. Panorama is a non-invasive prenatal screening test based on cell-free DNA. Signatera is a personalised cancer detection test that uses tumour-informed cfDNA analysis. Prospera monitors organ transplant rejection using cfDNA. The tests are backed by more than 300 peer-reviewed publications.

Natera operates CLIA-certified laboratories in Austin, Texas and San Carlos, California, and serves patients and healthcare providers worldwide. Laboratories hold ISO 13485 certification and CAP accreditation alongside CLIA certification. The company states its aim is to make personalised genetic testing and diagnostics part of the standard of care, with an emphasis on earlier and more targeted medical intervention.

Work at Natera sits at the intersection of several technical domains: cell-free DNA testing, genetic diagnostics, molecular biology, bioinformatics, AI, oncology genomics, prenatal screening and transplant monitoring.